Experience When It Matters Most
Our statewide physician network includes nationally recognized experts in cancer care and research—experience you want and deserve when it matters most.
Have a question? Call the clinic location closest to you, or our main number, 1-888-259-7622.
Comprehensive Care, Proven Outcomes
Since 1992, Rocky Mountain Cancer Centers (RMCC) has been a leader in cancer care. We began as a small group practice of six physicians with a new approach to treating cancer—administering chemotherapy on an outpatient basis—and have since developed into Colorado's largest and most comprehensive provider of cancer care with 58 physicians treating patients in 20 community-based locations across the state.
Through our culture of respect and collaboration we practice evidence-based medicine and participate in clinical research to create value and positive outcomes for our patients and families, referring physicians and payers.
Expertise in Rare and Common Cancers
No matter what cancer type you've been diagnosed with our team of nationally recognized doctors and support providers are here to help with personalized treatment plans that include the most advanced treatment options and therapies.
Experience When It Matters Most
Our statewide physician network includes nationally recognized experts in cancer care and research—experience you want and deserve when it matters most.View All Providers
Cancer Care Close To Home
With 20 outpatient cancer treatment centers across Colorado, we provide convenient, cost-effective, comprehensive cancer care close to home. Our state-of-the-art facilities have everything you need to fight cancer.
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations, NCT02365597
PURPOSE OF THIS CLINICAL RESEARCH TRIAL: The purpose of this study is to evaluate the objective response rate of the selected dose regimen out of 2 possible dose regimens of JNJ-42756493 in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations. MORE DETAILS ON THIS OVARIAN CANCER TRIAL: 14182 / NCT02365597 […]Read More
Treatment and Services
Are you concerned about your risk for cancer? Our board certified genetic counselors can help you learn about hereditary and other risks factors for cancer, as well as explain recent advances in cancer screening, cancer risk reduction strategies and genetic testing. Together with our medical oncologists they provide medical management recommendations and support for patients who have been diagnosed with or are at high risk for developing cancers such as breast, colorectal, prostate, gastrointestinal, uterine , ovarian and other cancersRead More
Multiple Myeloma: The Antibodies are Coming!
By John Burke, M.D.
For the past few years, researchers have been working on developing monoclonal antibodies to treat myeloma. Finally, the approval of at least a couple of such antibodies appears to be around the corner. Read More